| Arlington Family Practice P.c | |
|
22 Mill St Suite 101 Arlington MA 02476-4784 | |
| (781) 646-4345 | |
| (781) 646-5091 |
| Full Name | Arlington Family Practice P.c |
|---|---|
| Speciality | Family Medicine |
| Location | 22 Mill St, Arlington, Massachusetts |
| Authorized Official Name and Position | Ann M Morvai (OWNER) |
| Authorized Official Contact | 7816464345 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Arlington Family Practice P.c 22 Mill St Suite 101 Arlington MA 02476-4784 Ph: (781) 646-4345 | Arlington Family Practice P.c 22 Mill St Suite 101 Arlington MA 02476-4784 Ph: (781) 646-4345 |
| NPI Number | 1326016809 |
|---|---|
| Provider Enumeration Date | 03/09/2006 |
| Last Update Date | 05/12/2021 |
| Medicare PECOS PAC ID | 9335040906 |
|---|---|
| Medicare Enrollment ID | O20040116000287 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326016809 | NPI | - | NPPES |
| 690878 | Other | MA | TUFTS |
| M17832 | Other | MA | BCBS OF MASS |
| 9708961 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 75018 (Massachusetts) | Primary |
| Provider Name | Ann M Morvai |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063403608 PECOS PAC ID: 7719888395 Enrollment ID: I20040116000368 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
| Provider Name | Donald H Perlo |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366555260 PECOS PAC ID: 7315833480 Enrollment ID: I20040225000710 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
| Provider Name | Ani Tahmassian |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316111313 PECOS PAC ID: 4688715345 Enrollment ID: I20100104000471 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
| Provider Name | Erika E Line-nitu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376808766 PECOS PAC ID: 5597987941 Enrollment ID: I20150311001760 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
| Provider Name | April K Kavanagh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992168132 PECOS PAC ID: 3072801067 Enrollment ID: I20200701002249 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
Rewarding learning today can improve learning tomorrow; this is one of the conclusions reached by researchers from the Cognition and Brain Plasticity research group of the Institute of Biomedical Research of Bellvitge and the University of Barcelona in their last work on the impact of emotions on the way we remember things.
Group A streptococcus (GAS) is a human pathogenic bacteria. Many people carry GAS asymptomatically in their upper respiratory tract and other anatomic sites. However, these bacteria can cause a variety of human diseases ranging from superficial skin and throat infections to highly invasive life-threatening diseases such as toxic shock and necrotizing fasciitis, commonly known as the flesh-eating bacteria.
› Verified 6 days ago
Acupuncture & Qigong For Integral Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 366 Massachusetts Ave Ste 303, Arlington, MA 02474 Phone: 617-997-9922 Fax: 978-510-5356 | |
Rothfeld Center For Integrative Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 180 Massachusetts Ave, Suite 303, Arlington, MA 02474 Phone: 781-641-1901 Fax: 781-641-3963 | |
One Call Healthcare Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1 Farmer Cir, Arlington, MA 02474 Phone: 617-866-0789 | |
Everest Health Care Specialists Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 142 Lake St, Arlington, MA 02474 Phone: 781-777-2320 Fax: 781-777-1652 | |
Maureen Norman Do Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 22 Mill St, Suite 109, Arlington, MA 02476 Phone: 781-648-2970 Fax: 781-648-7077 | |
Family Practice Group Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11 Water St, Suite 1a, Arlington, MA 02476 Phone: 781-648-9700 Fax: 781-648-0234 |